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Abstract
Background. Non-dialysis-dependent chronic kidney dis-
ease (CKD) is related to cognitive impairment. Previous
studies have not explored the extent of impairment across
multiple cognitive domains. We examined the range of spe-
cific cognitive abilities affected by CKD and whether the
associations of CKD with cognition were eliminated by
statistical control for cardiovascular disease correlates of
CKD.
Methods. We performed a community-based cross-
sectional study with 923 individuals free from dementia
and end-stage renal disease. Two groupswere defined based
on estimated glomerular filtration rate (eGFR): eGFR<60
mL/min/1.73 m2 versus eGFR ≥ 60 mL/min/1.73 m2. Out-
come measures were scores from multiple clinical tests of
specific cognitive abilities. The GFR classifications and
serum creatinine levels were related to measures of cogni-
tive performance using logistic and linear regression anal-
yses with three sets of covariates: (1) basic (age, education,
gender and race); (2) basic+risk factors for cardiovascular
disease (CVD) and (3) basic+risk factors for CVD+stroke.
Results.An eGFR<60mL/min/1.73m2 was present in 142
(15.4%) individuals; the mean (SD) eGFR in this subgroup
was 49.7 (10.7). CKDwas related to lower cognitive perfor-
mance despite adjustment for CVD risk factors (CVD-RF).
Adjusting for CVD-RF and stroke, odds ratios and 95%
confidence intervals associated with performing in the low-
est quartile of the distribution of the Global, Visual–Spatial
Organization/Memory and Scanning and Tracking scores
for the eGFR < 60 group were 1.97 (1.25, 3.10); 1.88
(1.21, 2.93) and 1.83 (1.56, 2.87), P < 0.01 with eGFR ≥
60 group as the reference group.
Conclusions. Global performance and specific cognitive
functions are negatively affected early in CKD. Targeted
screening for cognitive deficits in kidney disease patients
early in their disease course may be warranted.
Keywords: cardiovascular disease; chronic kidney disease; cognitive
performance; serum creatinine
Introduction
End-stage renal disease (ESRD) and less advanced stages
of chronic kidney disease (CKD) are associated with cog-
nitive impairment [1–10]. The relation between CKD and
cognitive impairment is an important public health issue be-
cause the prevalence of CKD in the United States increased
from 10% between 1988 and 1994 to 13% between 1999
and 2004, and may rise further in the future [11].
Prior studies examining CKD and cognitive function
have reported an association of CKD with general cogni-
tive function, incident dementia and functioning cognitive
abilities related to verbal learning, visual attention, men-
tal flexibility and executive functioning [5–10]. However,
these studies either used clinic-based study samples, and
thus have more limited generalizability or employed a lim-
ited battery of neurocognitive tests.
The mechanisms proposed as mediators of relations be-
tween kidney function and cognition are similar to those
that have been advanced to explain relations between
other risk factors for cardiovascular disease and cognition,
e.g. atherosclerosis, clinical stroke, silent stroke, oxidative
stress and white matter lesions [7,12,13]. A number of tra-
ditional risk factors for cardiovascular disease (CVD) in-
cluding blood pressure, diabetes mellitus, body mass index
(BMI), smoking and low-HDL (high-density lipoprotein)
cholesterol have been identified as among the most impor-
tant independent risk factors for the onset of kidney disease
[14].
In the present study, we examined the relations of CKD
and lower renal filtration function with a broad range of
cognitive functions in a dementia-free community-based
population. We examined these relations before and after
adjustment for major CVD-RF [14] as well as for other
variables that confound relations between CKD and cog-
nition [15–17]. We hypothesized that modest attenuation
of the magnitude of relations between CKD and cognition
with adjustment for major CVD-RF would occur, but that
significant associations would remain.
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Methods
Sample and design
The data were obtained from the sixth wave of the Maine-Syracuse Lon-
gitudinal Study (MSLS), a community-based study of CVD-RF [18,19].
Participants were recruited from the Syracuse, NY, area for studies of cog-
nition and blood pressure with no requirements for participation other than
non-institutionalization, absence of diagnosed psychiatric disorder and/or
alcoholism. Between 2001 and 2006 (wave 6), data necessary to examine
a broad range of cognitive measures and CVD-RF, including creatinine
were obtained for the first time.
Beginning with 1047 study participants, individuals were excluded
in the following sequence: (1) data necessary to calculate eGFR were
missing (n = 82); (2) dementia (n = 9); (3) active dialysis treatment (n =
4) and (4) under 40 years of age (n = 29). The final sample consisted of
781 participants with eGFR ≥ 60 mL/min/1.73 m2 and 142 participants
with eGFR<60 mL/min/1.73 m2 (CKD group). The age exclusion was
employed because of a major imbalance in age between the two eGFR
groups when persons < 40 years old were included.
The clinical diagnosis of dementia was determined from cognitive
data and medical records using the National Institute of Neurological
and Communicative Diseases and Stroke/Alzheimer’s Disease and Re-
lated Disorders Association (NINCDS-ADRDA) criteria [20]. Exclusion
of dementia cases was based on our interest in characterizing relationships
between kidney disease and cognition in persons who vary in cognitive
ability, but who have not suffered major impairment.
Procedures
The participants completed the Center for Epidemiological Studies De-
pression Scale (CES-D) [21] within 1 week prior to neuropsychological
testing. Following a fast from midnight, a blood sample was drawn in
the morning, followed by a light breakfast, medical history, multiple au-
tomated blood pressure measurements (GE Dinamap 100DPC-120XEN)
and neuropsychological assessment. All assay methods have been de-
fined previously [18,19]. Serum creatinine (sCR) was determined using
a two-point rate test type on a Johnson and Johnson Vitros Instrument.
Coefficients of variation for these procedures were <5.0%. The eGFR
was estimated using the four-variable (sCR, age, sex and ethnicity) Mod-
ification of Diet in Renal Disease (MDRD) study equation [22,23]. Our
definition of CKD in this study does not include albuminuria.
Determinations of high-sensitivity C-reactive protein (CRP), serum vi-
tamin B12, total cholesterol, HDL cholesterol, LDL (low-density lipopro-
tein) cholesterol and glucose, homocysteine (Hcy) and standard ApoE
genotyping were performed as previously described [18,19,24]. To be
classified as anaemic, a diagnosis of anaemia or treatment for anaemia,
as established by medical records, was necessary. Haemoglobin levels and
complete blood count (CBC) were not available to the study, as we did not
anticipate an examination of kidney function as a risk factor at the time
the data were collected.
Mean systolic BP (SBP) and diastolic BP (DBP) were based on at
least 15 BP measurements (5 sitting, 5 standing and 5 reclining). Hy-
pertension was defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg
regardless of medication. Additional covariates used or considered in var-
ious analyses described later were as follows: race/ethnicity, defined as
African Americans versus other, treatment with antihypertensive medica-
tions, treatment with anti-cholesterol medications, diabetes mellitus, body
mass index (BMI, kg/m2), self-report of number of cigarettes smoked per
week, alcohol consumption (ounces per week), triglyceride levels, plasma
homocysteine (Hcy), self-reported presence of CVD confirmed by medi-
cal records and/or treatment and stroke. Diabetes mellitus was defined by
treatment with insulin, oral anti-diabetic agents or fasting glucose level of
126 mg/dL (7 mmol/L) or higher. CVD was defined as the presence of
any one of the following: myocardial infarction (4.3%), coronary artery
disease (8.1%), heart failure (2.5%), angina pectoris (6.0%) and transient
ischaemic attack (3.7%) [16,17]. Stroke, defined as a focal neurological
deficit of acute onset persisting more than 24 h, was based on self-report
or medical records, confirmed by record review, hospitalization or both.
Cognitive tests and domains
The cognitive outcome measures were four relatively independent and
theory-based composite scores that define the following cognitive do-
mains: Verbal Episodic Memory, Visual–Spatial Organization and Mem-
Table 1. Descriptions of the cognitive tests contributing to each com-
posite score indexing a cognitive domaina
Composite scores (domains)
and tests that define them
Cognitive ability measured
Verbal Episodic Memory
Logical memory—
immediate recallb
Immediate memory, verbal
Logical memory—delayed
recallb
Delayed memory, verbal
Hopkins Verbal Learning
Test
Verbal learning and memory
Visual–Spatial Organization/
Memory
Visual reproductions—
immediate recallb
Immediate recall, visual memory,
and visual–spatial problem solving
Visual reproductions—
delayed recallb
Delayed recall, visual memory and
visual–spatial problem solving
Matrix reasoningc Abstract reasoning and pattern
recognition
Block designd Visual–spatial perception,
organization and construction
Object assemblyd Speed of visual–spatial organization
Hooper Visual
Organization
Visual–spatial organization; some
demands on executive function
Scanning and Tracking
Trail making Ae Visual scanning and tracking;
concentration and attention
Trail making Be Trails A plus demands on executive
function abilities
Digit symbol substitutiond Psychomotor performance
Symbol searchc Visual processing speed
Working Memory
Digit span forwardd Attention and concentration
Digit span backwardd Attention, concentration and working
memory
Letter–number sequencec Information processing while
holding information in memory
Controlled Oral Word
Associations
Verbal fluency and executive
functioning
Similarities Verbal intelligence and abstract
reasoning
aThe tests employed in each composite score/domain define the abil-
ities measured by that domain. A general description of the cognitive
processes required by each domain of functioning may be found in the
text.
bOrigin Wechsler Memory Scale—revised.
cOrigin Wechsler Adult Intelligence Scale III.
dOrigin Wechsler Adult Intelligence Scale.
eOrigin Halstead–Reitan Neuropsychological Test Battery.
ory (VSOM), Scanning and Tracking and Working Memory. Briefly,
Verbal Episodic Memory is required for learning and memory of oral
or written material such as instructions. Visual–Spatial Organization and
Memory is required for problem solving with respect to visual–spatial
relationships. Scanning and Tracking requires attention and concentration
and places demands on organization and planning (executive functioning).
Working Memory requires holding information in short-term memory
while manipulating the information needed to execute a task [25–29].
The number of composite scores and the tests [25–29] used to define
each composite (domain of cognitive functioning) were based on principal
components and orthogonal rotation analyses employed in previous studies
with this sample [18,19] and confirmed in the present study. The 17
tests composing the composite scores (domains) are described in Table 1.
Similarities, a measure of abstract reasoning, correlated nearly equally
with each of the above domains and thus was treated as a separate measure
and only included in the Global composite.
Where necessary, raw test scores were first normalized (log to the
base 10 transformation) to achieve a normal distribution. Each individ-
ual’s original (raw) test score was then transformed to a z score, a linear
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transformation that allows all performance measures to be expressed in
the same units of measurement (SD units) and to have a distribution of
scores with mean = 0 and a SD = 1 [30]. Each individual’s composite
scores were the sum of the equally weighted [31,32] z scores making up
the composite divided by the number of tests in the composite and then
re-transformed to z scores as the final step. The Global score, based on all
tests, was calculated in the same way. See Supplement 1 for more details
on scoring.
The University of Maine IRB approved the protocol for this investiga-
tion. Informed consent for data collection was obtained from all partici-
pants and we adhered to the Declaration of Helsinki.
Statistical analyses
In the first set of analyses we compared the differences between the
eGFR ≥ 60 and eGFR<60 groups using logistic regression analysis, thus
permitting a determination of odds ratios associated with poor perfor-
mance, operationally defined as a cognitive score on any of the outcome
measures falling in the lowest quartile of the distribution of test scores.
This criterion for relatively poor performance (cognitive deficit) has been
used in previous studies, including publication of norms [33–35]. A person
performing at an average level within the lowest quartile of our sample
would have a z score 1.34 SD below the mean of the entire distribution of
test scores (z = −1.34).
The distributions of eGFR did not meet requirements for linear regres-
sion analysis as a continuously distributed variable [36] despite various
transformations. Moreover, while the four-variable MDRD study equation
is reasonably accurate for assigning participants to GFR groups based
on eGFR <60 and ≥60 mL/min/1.73 m2 values, it is of limited accu-
racy in estimating eGFR at higher levels [22,23]. Thus, following the
Cardiovascular Health Study [10], in the second set of analyses we em-
ployed a normalized distribution of creatinine (1/sCR) values in linear
regression analyses relating renal insufficiency to cognitive performance.
Because we adjusted for factors aside from renal function that are known
to influence serum creatinine (i.e. age, gender and body mass index), the
observed associations of 1/sCR with cognitive performance in these mul-
tivariate models can be interpreted as representing primarily the effects
of renal filtration function. Using the general linear model (SAS version
9.1), multivariable regression analyses were performed separately for each
independent variable.
The statistical models were based on the identification of independent
predictors of new-onset kidney disease in the Framingham Heart Study
[14], many of which are also hypothesized risk factors for neurocognitive
deficit [15–17]. For each of the major analyses, i.e. linear regression using
1/sCR and the logistic regression analyses using GFR groups, sets of
covariates were introduced in serial stepwise order: (1) basic model =
age (years) + gender + education (years) + race; (2) basic + CVD-RF
model = basic model + mean SBP + diabetes mellitus + BMI + HDL
cholesterol + number of cigarettes smoked per day and (3) basic model +
CVD-RF model + Stroke. Additional covariates described in the results
section were employed in planned secondary sets of analyses.
Residual plots, absence of non-linear trends (P-values > 0.20) and a
low Variance Inflation Factor, 1.14–1.50, [36,37] confirmed the appropri-
ateness of the straight-line fit for 1/sCR and the absence of collinearity.
However, Hcy was highly correlated with creatinine, Pearson’s r = 0.43,
and may be a proxy for renal disease. Thus, it was not included as a
covariate in the analyses.
Results
Demographic, health and kidney function characteristics
of our non-demented and well-educated cross-sectional,
community-based sample of middle aged to elderly adults
(60% women; 7.3% African American) are presented in
Table 2. Participants with CKDwere older, exhibited higher
CRP, higher mean SBP, higher Hcy, lower HDL cholesterol,
higher creatinine, consumed moderately less alcohol and
there was a higher proportion of persons with diabetes and
cardiovascular disease.
Table 2. Demographic and health characteristics of participants by level
of renal function
Variable eGFR ≥ 60
mL/min/1.73
m2 (n = 781)
eGFR < 60
mL/min/1.73
m2 (n = 142)
P-value
Mean SD Mean SD
Age (years) 62.3 11.7 68.5 11.6 0.0001
Education (years) 14.6 2.7 14.2 2.7 0.1341
CRP (mg/L) 4.0 4.4 5.0 5.9 0.0152
Homocysteine (mmol/L) 9.5 3.3 13.2 4.8 0.0001
Total cholesterol (mg/dL) 202.0 39.7 202.6 42.6 0.8707
HDL cholesterol (mg/dL) 53.9 15.6 51.1 14.3 0.0424
LDL cholesterol (mg/dL) 121.0 33.3 119.7 34.6 0.6737
Mean SBP, exams
1–6 (mmHg)
131.2 19.0 137.5 20.6 0.0004
Mean DBP, exams
1–6 (mmHg)
73.1 10.6 73.8 11.4 0.4590
Cigarettes/day 1.3 5.3 1.2 4.5 0.9600
BMI (kg/m2) 29.4 6.0 29.9 6.0 0.4100
Alcohol (oz/week) 1.5 2.8 1.0 1.7 0.0222
Creatinine (mg/dL) 0.9 0.2 1.4 0.7 0.0001
eGFR (mL/min/1.73 m2) 83.4 14.3 49.7 10.7 0.0001
Percent Percent
Women 58.2 63.8 0.2536
African American 7.3 7.3 0.8508
Diabetes mellitus 12.6 23.9 0.0002
ApoE-ε4 26.4 27.5 0.7848
Folate deficiency
(>3 ng/mL)
0.3 1.4 0.1051
B12 deficiency
(<200 pg/mL)
3.3 4.2 0.6010
Depressed mood
(CES-D > 16)
10.3 12.1 0.5249
Anaemia 1.7 4.2 0.0742
Stroke 2.3 6.4 0.0404
Cardiovascular diseasea 13.6 26.1 0.0002
aCardiovascular disease includes a diagnosis of myocardial infarction,
coronary artery disease, heart failure, angina pectoris and transient is-
chaemic attack.
Table 3 summarizes the odds ratios associated with per-
formance in the lowest quartile as a function of membership
in the GFR< 60 group with GFR ≥ 60 serving as the ref-
erence group. With adjustment for the basic covariate set,
significantly higher odds of poor performance were associ-
atedwithmembership in theGFR< 60 group for theGlobal,
VSOMandScanning andTracking composites and Similar-
ities (abstract reasoning). With adjustment for the Basic +
CVD-RF and the Basic+CVD-RF+ Stroke covariate sets,
the same significant results were obtained except for a non-
significant association of CKDwith Similarities. There was
only amodest attenuation of odds ratios with adjustment for
the covariate sets. Thus, for example, odds of performance
score in the lowest quartile for the Global Composite score
were 2.27, 1.97 and 1.97, respectively with adjustment for
the Basic, Basic + CVD-RF and the Basic + CVD-RF +
Stroke covariate sets. Results for individual test scores are
summarized in Supplement 2.
Risk of cognitive deficit for persons in the GFR < 60
group can be put in further perspective by comparing them
with risk associated with diabetes mellitus, an established
risk factor for neurocognitive deficit [38], using the Global
Composite scores as an example. The odds ratio associated
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Table 3. Results of logistic regression analysis showing odds ratios (OR) and confidence intervals (CI) for performing in the lowest quartile of cognitive
scores for persons with GFR < 60 (GFR ≥ 60 is the reference group) and P-values for differences between groups
Cognitive measure Basic modela Basic + CVD-RFb Basic + CVD-RF + Strokec
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Global Composite 2.27 1.47, 3.52 0.0002 1.97 1.25, 3.09 0.0032 1.97 1.25, 3.10 0.0035
Visual–Spatial Organization and 2.00 1.31, 3.07 0.0016 1.88 1.21, 2 .93 0.0051 1.88 1.21, 2.93 0.0052
Memory
Verbal Memory 1.37 0.91, 2.08 0.1319 1.24 0.81, 1.90 0.3145 1.26 0.82, 1.93 0.2947
Working Memory 1.38 0.91, 2.09 0.1285 1.20 0.78, 1.83 0.4088 1.21 0.79, 1.87 0.3810
Scanning and Tracking 2.01 1.30, 3.12 0.0018 1.83 1.17, 2.87 0.0086 1.83 1.56, 2.87 0.0094
Similarities (abstract reasoning) 1.58 1.01, 2.48 0.0475 1.39 0.87, 2.21 0.1665 1.38 0.87, 2.21 0.1738
aCovariates in the Basic model are age, sex, education and race.
bCovariates in the Basic + CVD-RF model are age, sex, education, race, diabetes, SBP, BMI, cigarettes/day and HDL.
cCovariates in the Basic+ CVD-RF + Stroke model are age, sex, education, race, diabetes, SBP, BMI, cigarettes/day, HDL and stroke.
Table 4. Summary of P-values describing the significance of the regression coefficients relating creatinine to the cognitive measures and the difference
(decrement) in performance (z scores) associated with an increment in the creatinine level from 1 to 2 mg/dL
Cognitive measure Basic modela Basic + CVD-RFb Basic + CVD-RF + Strokec
P-value 2 vs 1 mg/dL P-value 2 vs 1 mg/dL P-value 2 vs 1 mg/dL
Global Composite 0.009 −0.1480 0.031 −0.1207 0.040 −0.1152
Visual–Spatial Organization and 0.010 −0.1551 0.026 −0.1338 0.576 −0.0377
Memory
Verbal Episodic Memory 0.373 −0.0600 0.527 −0.0426 0.028 −0.1327
Working Memory 0.117 −0.1088 0.265 −0.0774 0.280 −0.0752
Scanning and Tracking 0.009 −0.1506 0.023 −0.1303 0.042 −0.1163
Similarities (abstract reasoning) 0.148 −0.0933 0.301 −0.0666 0.577 −0.0329
aCovariates in the Basic model are age, sex, education, and race.
bCovariates in the Basic + CVD-RF model are age, sex, education, race, diabetes, SBP, BMI, cigarettes/day and HDL.
cCovariates in the Basic + CVD-RF + Stroke model are age, sex, education, race, diabetes, SBP, BMI, cigarettes/day, HDL and stroke.
with diabetes for deficit on the Global Composite score
was 1.60 (95% CI = 1.02, 2.51); the odds ratio associ-
ated with low eGFR was considerably higher, at 2.27 (95%
CI = 1.47, 3.52).
Table 4 summarizes the results of linear regression anal-
yses employing 1/sCR as the predictor. In order to make
the regression coefficients meaningful in terms of specific
creatinine levels, they are expressed as the difference in
performance levels (z scores) between 1 and 2 mg/dL crea-
tinine (as predicted by the regression equation). The minus
signs indicate a decrement in performance with an increase
in creatinine from 1 to 2 mg/dL. Regardless of adjustment
for the various covariates, higher levels of sCRwere associ-
atedwith lower cognitive performance levels for theGlobal,
VSOM and Scanning and Tracking composites for all three
sets of covariates. For example, comparing participantswith
creatinine levels of 1.0 mg/dL versus 2.0 mg/dL, with ad-
justment for age, education, gender and race, the participant
with the higher creatinine level would be predicted to score
−0.15 SD (15% of 1 SD lower) on the VSOM composite
score (Table 4).
Composite scores do not have raw (original) scores, but
the results for individual tests can be expressed as raw
scores and z scores. Thus, the meaning of the levels of
deficit expressed in z scores (units of SD) in Table 4 can
be illustrated by comparing predicted z scores and original
raw test scores for a test that contributed significantly to the
VSOMscore in the 1/sCRanalysis, i.e. theObjectAssembly
Test. The predicted decrement in performance for persons
with 2 mg/dL creatinine versus 1 mg/dL creatinine is 1.86
raw score points (z = −0.20 or 20% of 1 SD).
The following covariables were added to the basic model
for the logistic and linear regression analyses described
above: depressed mood (CES-D > 16) [21], CRP, alco-
hol consumption, ApoE genotype, anti-hypertensive drugs
(yes/no), anti-cholesterol drugs (yes/no) and cardiovascu-
lar disease (yes/no). The pattern of significant results was
the same as that previously reported (Tables 3 and 4). Fur-
ther, the pattern of results was unchanged when either mean
DBP or hypertension were substituted for SBP and when
total cholesterol, LDL cholesterol or triglycerides were sub-
stituted for HDL in the Basic + CVD-RF covariate set.
Discussion
The odds of performance decrement in the Global, VSOM
and Scanning and Tracking performance domains of func-
tioning were significantly higher for those with low eGFR
regardless of the statistical models employed. Similarly,
higher levels of creatinine were associated with lower lev-
els of performance for theGlobal, VSOMand Scanning and
Tracking domains even after adjustment for demographics,
cardiovascular risk factors and stroke.
Poor performance on the Global score is consistent with
previous studies employing the MMSE [5] or a six-item
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telephone screening instrument [2] and reflects the general
trend across all measures for lower levels of performance
in relation to higher creatinine levels and membership
in the GFR< 60 group. However, it is important to note that
the Global Composite score is not directly comparable to
the MMSE or telephone screening measures. The MMSE
was designed to be a measure of mental status and is subject
to significant ceiling effects (most test questions are insuf-
ficiently difficult) in persons who are free from dementia.
While particularly useful for large population studies of
kidney disease, the six-item screening instrument is a rel-
atively insensitive measure of cognitive function and does
not test specific cognitive abilities [2].
Our findings demonstrate a decreased performance level
within specific domains of cognition in association with
modestly lower renal function. For example, the risk of
performing in the lowest quartile for Global, VSOM and
Scanning and Tracking is doubled in the presence of
GFR < 60 and approaches this level with adjustment of
the covariates. Diabetes is well established as a risk factor
for cognitive impairment [33,38], but the odds ratios associ-
ated with performance in the lowest quartile for the Global
Composite score were less for diabetics (OR = 1.60) than
for persons in the GFR<60 group (OR = 2.27). Given the
high prevalence of CKD in the USA, the public health im-
plications of moderate decrements in performance for CKD
patients are considerable [11].
Neuropathological changes in the brain that parallel
changes in kidney have been posited as mechanisms ex-
plaining relationships between CKD and cognition [34].
These include atherosclerosis, microvascular disease, clin-
ical stroke, silent stroke, oxidative stress and white mat-
ter lesions [7,12,13,39,40]. For example, in a recent study
of homebound elderly individuals, albuminuria was associ-
ated with lower levels of executive function ability and with
white matter hyperintensities andwhite matter volume [41].
Disease-related depression can contribute to lower cog-
nitive performance but our results were robust to statistical
adjustment of depressive symptoms. The absence of neu-
roimaging studies in the present investigation prevents us
from inferring which specific areas of the brain are asso-
ciated with the observed cognitive deficits. However, it is
clear that specific cognitive domains are more vulnerable
to moderate CKD, i.e. VSOM and Scanning and Track-
ing abilities. Deficits in VSOM manifest in deficits in vi-
sual pattern recognition, immediate and delayed memory
for visual materials, and organization and problem solving
in a visual–spatial context [28,29]. Deficits in Scanning
and Tracking reflect lowered ability in attention, concen-
tration, visual processing speed, psychomotor performance
and planning resulting in difficulty with completing an or-
ganized visual search [28,29]. In contrast, neither Working
Memory nor Verbal EpisodicMemory was significantly as-
sociated with CKD. Patients exhibiting the pattern of cog-
nitive deficits seen in this study would not be expected to
have difficulty in remembering well-organized specific in-
structions for medications and fluid and dietary restrictions
presented verbally or in writing, but may experience diffi-
culty when challenged by higher order demands on visual–
spatial memory and organization, concentration, scanning
and tracking, psychomotor and executive skills, e.g. avia-
tion and air traffic control.
There are two broader concerns: (1) modest cognitive
deficits, especially deficits in visual–spatial skills, are risk
factors for later, more serious impairments in cognition, in-
cluding dementia [42,43,44] and (2) more severe cognitive
impairment extending to memory may be seen in more ad-
vanced CKD [13,45]. Earlier studies have shown that cog-
nitive impairment is a complication of advanced pre-ESRD
and ESRD patients on maintenance dialysis [1–6,13]. Our
results indicate that cognitive function is reduced even in
patients with only moderate reductions in GFR, and that
visual–spatial organization and memory and scanning and
tracking functions are particularly vulnerable. Thus aware-
ness and treatment of cognitive deficits should begin early
in the progression of kidney disease.
Limitations
The absence of haemoglobin determinations and standard-
ization of creatinine values are limitations because the study
was not designed to delineate the association of kidney dis-
ease with cognition at the time of data collection. However,
our community-based study permitted us to examine re-
lationships between CKD and cognition in a non-clinical
sample, unselected for kidney disease and with blinded
testing procedures.
Our participants were relatively highly educated. Edu-
cation is protective of cognitive performance [46,47]; con-
sequently, our findings may underestimate the magnitude
of relations between renal function and cognition. We used
eGFR data obtained on only one occasion to define CKD.
However, our eGFR criterion was consistent with previous
community-based studies and the Hope 2 trial that defined
CKD in this manner [7–9,48]. Acute decrements in renal
function would not be anticipated in our relatively healthy
community-based study participants. Finally, our study was
cross-sectional and thus does not allow us to determine
causal directions between predictor and covariates.
Strengths
Strengths of our study include (1) a community-based sam-
ple; (2) data on CKD and multiple cardiovascular risk fac-
tors and (3) an extensive battery of neuropsychological tests
organized into theoretically relevant cognitive domains.
Perspectives
Hopefully our investigation will encourage much needed
longitudinal studies of cognitive decline in mild renal dis-
ease. Improvements in cognition following kidney trans-
plant [45] offer encouragement for intervention strategies
at the ESRD stage, but it is clear that early recognition and
treatment of modest cognitive deficits in CKD is important
[49] because patients with modest deficits are at risk for
the more serious cognitive impairments typical of ESRD.
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